Highly Efficient Ligands for Dihydrofolate Reductase from Cryptosporidium hominis and Toxoplasma gondii Inspired by Structural Analysis
Citations Over TimeTop 10% of 2007 papers
Abstract
The search for effective therapeutics for cryptosporidiosis and toxoplasmosis has led to the discovery of novel inhibitors of dihydrofolate reductase (DHFR) that possess high ligand efficiency: compounds with high potency and low molecular weight. Detailed analysis of the crystal structure of dihydrofolate reductase-thymidylate synthase from Cryptosporidium hominis and a homology model of DHFR from Toxoplasma gondii inspired the synthesis of a new series of compounds with a propargyl-based linker between a substituted 2,4-diaminopyrimidine and a trimethoxyphenyl ring. An enantiomerically pure compound in this series exhibits IC50 values of 38 and 1 nM against C. hominis and T. gondii DHFR, respectively. Improvements of 368-fold or 5714-fold (C. hominis and T. gondii) relative to trimethoprim were generated by synthesizing just 14 new analogues and by adding only a total of 52 Da to the mass of the parent compound, creating an efficient ligand as an excellent candidate for further study.
Related Papers
- → Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii.(1993)94 cited
- → Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii thymidylate synthase–dihydrofolate reductase(2014)10 cited
- → Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice(2018)2 cited
- → Efficacy of Epiroprim (Ro11-8958), a New Dihydrofolate Reductase Inhibitor, in the Treatment of Acute Toxoplasma Infection in Mice(1996)13 cited
- → Structural studies of dihydrofolate reductase-thymidylate synthase from Toxoplasma gondii and dynamin 1 from Rattus norvegicus.(2008)